Global Recombinant Human Growth Hormone Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Recombinant Human Growth Hormone Market Research Report 2024
Recombinant human growth hormone is produced by gene recombinant Escherichia coli secretory expression technology, and it is completely consistent with human pituitary growth hormone in amino acid content, sequence and protein structure. In the field of pediatrics, replacement therapy with recombinant human growth hormone can significantly promote children's height growth and improve the growth and development of various organs and tissues throughout the body. At the same time, recombinant human growth hormone also plays an important role in the fields of reproduction, burns and anti-aging.
According to Mr Accuracy reports new survey, global Recombinant Human Growth Hormone market is projected to reach US$ 7400.2 million in 2029, increasing from US$ 4268 million in 2022, with the CAGR of 8.2% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Recombinant Human Growth Hormone market research.
Key manufacturers engaged in the Recombinant Human Growth Hormone industry include Novo Nordisk, LG Chem, Pfizer, Eli lilly, Merck Serono, F.Hoffmann-La Roche, Ispen, Sandoz International and Changchun High-Tech Industries, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Recombinant Human Growth Hormone were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Recombinant Human Growth Hormone market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Recombinant Human Growth Hormone market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Novo Nordisk
LG Chem
Pfizer
Eli lilly
Merck Serono
F.Hoffmann-La Roche
Ispen
Sandoz International
Changchun High-Tech Industries
Shenzhen Kexing Pharmaceutical
Changchun GeneScience Pharmaceutical
Anhui Anke Biotechnology
Segment by Type
Powder Injection
Water Injection
Childhood Growth Hormone Deficiency
Chronic Renal Insufficiency
HIV Infection-Associated Wasting Syndrome
Adult GHD Replacement Therapy
Small For Gestational Age (SGA)
Others
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Recombinant Human Growth Hormone report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports new survey, global Recombinant Human Growth Hormone market is projected to reach US$ 7400.2 million in 2029, increasing from US$ 4268 million in 2022, with the CAGR of 8.2% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Recombinant Human Growth Hormone market research.
Key manufacturers engaged in the Recombinant Human Growth Hormone industry include Novo Nordisk, LG Chem, Pfizer, Eli lilly, Merck Serono, F.Hoffmann-La Roche, Ispen, Sandoz International and Changchun High-Tech Industries, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Recombinant Human Growth Hormone were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Recombinant Human Growth Hormone market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Recombinant Human Growth Hormone market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Novo Nordisk
LG Chem
Pfizer
Eli lilly
Merck Serono
F.Hoffmann-La Roche
Ispen
Sandoz International
Changchun High-Tech Industries
Shenzhen Kexing Pharmaceutical
Changchun GeneScience Pharmaceutical
Anhui Anke Biotechnology
Segment by Type
Powder Injection
Water Injection
Segment by Application
Childhood Growth Hormone Deficiency
Chronic Renal Insufficiency
HIV Infection-Associated Wasting Syndrome
Adult GHD Replacement Therapy
Small For Gestational Age (SGA)
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Recombinant Human Growth Hormone report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices